# REVIEW SERIES: INTERACTIONS OF THE MICROBIOTA WITH THE MUCOSAL IMMUNE SYSTEM

# Immune mechanisms of FMT in UC

1. Jacob V, Crawford C, Cohen-Mekelburg S et al. Single delivery of high-diversity fecal microbiota preparation by colonoscopy is safe and effective in increasing microbial diversity in active ulcerative colitis. Inflamm Bowel Dis 2017; 23:903–11.
2. Landy J, Walker AW, Li JV et al. Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. Sci Rep 2015; 5:12955.
3. Gogokhia L, Buhrke K, Bell R et al. Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. Cell Host Microbe 2019; 25:285–99.e8.
4. Wang Y, Wiesnoski DH, Helmink BA et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 2018; 24:1804–8.
5. Wang F, Yin Q, Chen L, Davis MM. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc Natl Acad Sci USA 2018; 115:157–61.
6. Rossen NG, Fuentes S, van der Spek MJ et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015; 149: 110–8.e4.
7. Paramsothy S, Kamm MA, Kaakoush NO et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017; 389:1218–28.
8. Paramsothy S, Nielsen S, Kamm MA et al. Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology 2019; 156:1440–54.e2.
9. Moayyedi P, Surette MG, Kim PT et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015; 149:102–9.e6.
10. Burrello C, Garavaglia F, Cribiu FM et al. Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. Nat Commun 2018; 9:5184.
11. Wei YL, Chen YQ, Gong H et al. Fecal microbiota transplantation ameliorates experimentally induced colitis in mice by upregulating AhR. Front Microbiol 2018; 9:1921.
12. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012; 489:231–41.
13. Kawajiri K, Fujii-Kuriyama Y. The aryl hydrocarbon receptor: a multifunctional chemical sensor for host defense and homeostatic maintenance. Exp Anim 2017; 66:75–89.
14. Bessede A, Gargaro M, Pallotta MT et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 2014; 511:184–90.
15. Ekmekciu I, von Klitzing E, Fiebiger U et al. Immune responses to broad-spectrum antibiotic treatment and fecal microbiota transplantation in mice. Front Immunol 2017; 8:397.
16. Ekmekciu I, von Klitzing E, Neumann C et al. Fecal microbiota transplantation, commensal Escherichia coli and Lactobacillus johnsonii strains differentially restore intestinal and systemic adaptive immune cell populations following broad-spectrum antibiotic treatment. Front Microbiol 2017; 8:2430.
17. Li M, Liang P, Li Z et al. Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis. Front Microbiol 2015; 6:692.
18. Perry T, Jovel J, Patterson J et al. Fecal microbial transplant after ileocolic resection reduces ileitis but restores colitis in IL-10−/− mice. Inflamm Bowel Dis 2015; 21:1479–90.
19. Hensley-McBain T, Zevin AS, Manuzak J et al. Effects of fecal microbial transplantation on microbiome and immunity in simian immunodeficiency virus-infected macaques. J Virol 2016; 90:4981–9.
20. van Herk EH, Te Velde AA. Treg subsets in inflammatory bowel disease and colorectal carcinoma: characteristics, role, and therapeutic targets. J Gastroenterol Hepatol 2016; 31:1393–404.
21. Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 2016; 165:1332–45.
22. Wang L, Liu Y, Han R et al. FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3. J Clin Invest 2015; 125:1111–23.
23. Smith PM, Howitt MR, Panikov N et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341:569–73.
24. Zeng H, Chi H. Metabolic control of regulatory T cell development and function. Trends Immunol 2015; 36:3–12.
25. Sun M, Wu W, Chen L et al. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. Nat Commun 2018; 9:3555.
26. Chakravortty D, Koide N, Kato Y et al. The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells. J Endotoxin Res 2000; 6:243–7.
27. Furusawa Y, Obata Y, Fukuda S et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504:446–50.
28. Vedanta Biosciences. VE202. Cambridge, MA: Vedanta Biosciences. Available at: https://www.vedantabio.com/pipeline/ve202.
29. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008; 453:620–5.
30. Dasgupta S, Erturk-Hasdemir D, Ochoa-Reparaz J, Reinecker HC, Kasper DL. Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms. Cell Host Microbe 2014; 15:413–23.
31. Round JL, Lee SM, Li J et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011; 332:974–7.
32. Kreisman LS, Cobb BA. Glycoantigens induce human peripheral Tr1 cell differentiation with gut-homing specialization. J Biol Chem 2011; 286:8810–8.
33. Bakdash G, Vogelpoel LT, van Capel TM, Kapsenberg ML, de Jong EC. Retinoic acid primes human dendritic cells to induce

© 2019 British Society for Immunology, Clinical and Experimental Immunology, 199: 24–38